DOI: http://dx.doi.org/10.18203/2349-3933.ijam20201606

Angiopoietin 2 in type 2 diabetes mellitus patients and those with complications: an observational comparative study

Kishan Raj K.

Abstract


Background: Angiopoietin 2 levels in blood signifies neo vascularization. Only biomarker available now for routine check up is HbA1c. However, it doesn’t suggest if patient is more prone to get into complications than the other. Here, we try to bring in another biomarker Angiopoietin 2 and elucidate if it can identify patients going in for complications of type 2 diabetes mellitus early.

Methods: Total 60 diabetic patients were studied over a span of 1 year. 30 were diabetic without any complciations and another 30 were with complications (Diabetic foot ulcer, Diabetic retinopathy, Diabetic nephropathy, Diabetic neuropathy). Angiopoietin 2 levels were estimated in both the groups and compared.

Results: Analysis showed Mean duration of Diabetes was significantly lower in patients without complication than those with complications. Human angiopoietin 2 levels were elevated in both the study groups. More so, in the study group with Diabetic patients with complications. It was statistically significant. (p<0.001).There was no significant relationship between duration of diabetes and Human angiopoietin 2 levels.

Conclusions: It was found that angiopoietin 2 is also a good biomarker for diabetes as HbA1c. It also helps in detection of complications earlier and thus may help in reducing morbidity as well as mortality. Further studies are required to strengthen the information got from this study to compare efficacy of HbA1c and angiopoietin 2 as well as how early can we detect the patients who may land up in complications.

 


Keywords


Angiopoietin 2, Complications of Type 2 diabetes mellitus, Type 2 diabetes mellitus

Full Text:

PDF

References


Huisman TH, Martis EA, Dozy A. Chromatography of hemoglobin types on carboxymethylcellulose. J Lab Clin Med. 1958;52(2):312-27.

Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Engl J Med. 1976;295(8):417-20.

Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91(3):813-9.

Colette C, Monnier L. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes. Horm Metab Res. 2007;39(9):683-6.

Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer letters. 2013 Jan 1;328(1):18-26.

Kronenberg H. In: Bruse JB, Polonsky KS, Burant CF. Type 2 diabetes mellitus in William textbook of endocrinology. 11th edition. Saunders; 2008:1936.

Woolf AS, Gnudi L, Long DA. Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol. 2009;20:239-44.

Zuliani-Alvarez L, Midwood KS. Fibrinogen-Related Proteins in Tissue Repair: How a Unique Domain with a Common Structure Controls Diverse Aspects of Wound Healing. Adv Wound Care (New Rochelle). 2015;4(5):273-85.

Anuradha S, Mohan V, Gokulakrishnan K, Dixit M. Angiopoietin-2 levels in glucose intolerance, hypertension, and metabolic syndrome in Asian Indians (Chennai Urban Rural Epidemiology Study–74). Metab. 2010 Jun 1;59(6):774-9.

Li L, Qian L, Yu ZQ. Serum angiopoietin-2 is associated with angiopathy in type 2 diabetes mellitus. J Diab Complications. 2015 May-Jun;29(4):568-71.